|
Substance (Drug) Abuse – Pipeline Review, H1 2012
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 177 seiten | |||||||||
| Inhalt der Studie: |
Introduction
Global Markets Direct’s, 'Substance (Drug) Abuse - Pipeline Review, H1 2012', provides an overview of the Substance (Drug) Abuse therapeutic pipeline. This report provides information on.....
Introduction Global Markets Direct’s, 'Substance (Drug) Abuse - Pipeline Review, H1 2012', provides an overview of the Substance (Drug) Abuse therapeutic pipeline. This report provides information on the therapeutic development for Substance (Drug) Abuse, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Substance (Drug) Abuse. 'Substance (Drug) Abuse - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Substance (Drug) Abuse. - A review of the Substance (Drug) Abuse products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Substance (Drug) Abuse pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Highlights Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Substance (Drug) Abuse. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Substance (Drug) Abuse pipeline depth and focus of Substance (Drug) Abuse therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. [Studien Infos ausblenden] |
|||||||||||
|
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Substance (Drug) Abuse Overview 8 Therapeutics Development 9 An Overview of Pipeline Products for Substance (Drug) Abuse 9 Substance (Drug) Abuse Therapeutics under Development by Companies 11 Substance (Drug) Abuse Therapeutics under Investigation by Universities/Institutes 13 Late Stage Products 17 Comparative Analysis 17 Mid Clinical Stage Products 18 Comparative Analysis 18 Early Clinical Stage Products 19 Comparative Analysis 19 Discovery and Pre-Clinical Stage Products 20 Comparative Analysis 20 Substance (Drug) Abuse Therapeutics – Products under Development by Companies 21 Substance (Drug) Abuse Therapeutics – Products under Investigation by Universities/Institutes 22 Companies Involved in Substance (Drug) Abuse Therapeutics Development 29 Alkermes, Inc. 29 Nippon Shinyaku Co., Ltd. 30 Mundipharma International Limited 31 Snowdon Inc. 32 KYORIN Pharmaceutical Co., Ltd. 33 Embera NeuroTherapeutics, Inc. 34 Celtic Pharmaceutical Holdings L.P. 35 Substance (Drug) Abuse – Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Combination Products 37 Assessment by Route of Administration 38 Assessment by Molecule Type 40 Drug Profiles 42 ALKS 33 - Drug Profile 42 MN-166 - Drug Profile 44 NS-11 - Drug Profile 46 Lofexidine + Marinol - Drug Profile 47 Modafinil - Drug Profile 48 N-Acetylcysteine - Drug Profile 49 Modafinil - Drug Profile 50 Risperdal - Drug Profile 51 Atomoxetine - Drug Profile 52 Lofexidine + Tetrahydrocannabinol - Drug Profile 53 N-Acetyl Cysteine + Naltrexone - Drug Profile 55 Vivitrol - Drug Profile 56 Chantix - Drug Profile 57 Modafinil - Drug Profile 59 Zyban - Drug Profile 60 Nabilone - Drug Profile 61 Adderall XR - Drug Profile 62 Remeron - Drug Profile 63 Aripiprazole - Drug Profile 64 Naltrexone - Drug Profile 65 Zofran - Drug Profile 66 Flumazenil - Drug Profile 67 Sevre-Long - Drug Profile 68 TA-CD Vaccine - Drug Profile 69 Ondansetron + Topiramate - Drug Profile 71 Ativan - Drug Profile 73 Pentobarbital - Drug Profile 74 Aripiprazole - Drug Profile 75 Mirtazapine - Drug Profile 76 Neurontin - Drug Profile 77 Lithium Carbonate - Drug Profile 78 Naltrexone - Drug Profile 79 Adderall-XR + Topiramate - Drug Profile 81 Dextro-Amphetamine - Drug Profile 82 Naltrexone + Dronabinol - Drug Profile 83 Naltrexone + Varenicline - Drug Profile 84 Naltrexone + Valproate - Drug Profile 86 Oral THC + Marijuana - Drug Profile 87 Dextro amphetamine sulfate + Modafinil - Drug Profile 89 Naltrexone + Varenicline - Drug Profile 90 TA-CD - Drug Profile 91 Memantine - Drug Profile 92 paroxetine, desipramine, naltrexone - Drug Profile 93 tramadol + hydromorphone + methylphenidate - Drug Profile 95 Naltrexone + Baclofen - Drug Profile 97 Nicoderm CQ + Nicotine Nasal Spray - Drug Profile 98 Levodopa + Carbidopa - Drug Profile 99 Naltrexone + Disulfiram - Drug Profile 100 Disulfiram - Drug Profile 101 Baclofen - Drug Profile 102 Gabapentin - Drug Profile 103 levodopa - Drug Profile 104 Lofexidine - Drug Profile 105 Lofexidine + THC - Drug Profile 106 Methylphenidate - Drug Profile 107 Methylphenidate - Drug Profile 108 Mirtazapine - Drug Profile 109 Modafinil - Drug Profile 110 Naltrexone - Drug Profile 111 Topamax - Drug Profile 112 Aripiprazole - Drug Profile 113 Atomoxetine - Drug Profile 114 bupropion - Drug Profile 115 Buspirone + Motivational enhancement therapy - Drug Profile 117 Buspirone + Motivational enhancement therapy - Drug Profile 118 Caffeine - Drug Profile 119 Chantix - Drug Profile 120 Citicoline - Drug Profile 121 Cycloserine - Drug Profile 122 Dextroamphetamine - Drug Profile 123 Disulfiram - Drug Profile 124 Donepezil - Drug Profile 125 Dronabinol - Drug Profile 126 Neurontin - Drug Profile 127 Keppra - Drug Profile 128 Mifepristone - Drug Profile 129 Modafinil - Drug Profile 130 Naltrexone - Drug Profile 131 olanzapine - Drug Profile 132 Oxycodone - Drug Profile 133 Prometa - Drug Profile 134 TYolcapone - Drug Profile 135 Transdermal Nicotine - Drug Profile 136 Vigabatrin - Drug Profile 137 TA-CD - Drug Profile 138 Topiramate - Drug Profile 140 Naltrexone + Modafinil - Drug Profile 141 Dextroamphetamine - Drug Profile 142 Coreg CR - Drug Profile 143 Methadone + Memantine - Drug Profile 144 Tramadol ER - Drug Profile 145 Tramadol - Drug Profile 146 Memantine - Drug Profile 147 Bupropion SR - Drug Profile 148 Varenicline - Drug Profile 149 Tacrine - Drug Profile 150 Substance (Drug) Abuse Therapeutics – Drug Profile Updates 151 Substance (Drug) Abuse Therapeutics – Discontinued Products 155 Substance (Drug) Abuse Therapeutics - Dormant Products 156 Substance (Drug) Abuse – Product Development Milestones 162 Featured News & Press Releases 162 Appendix 169 Methodology 169 Expert Panel Validation 170 Contact Us 170 Disclaimer 170 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Number of Products Under Development for Substance (Drug) Abuse, H1 2012 16 Products under Development for Substance (Drug) Abuse – Comparative Analysis, H1 2012 17 Number of Products under Development by Companies, H1 2012 19 Number of Products under Investigation by Universities/Institutes, H1 2012 21 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 22 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 23 Comparative Analysis by Late Stage Development, H1 2012 24 Comparative Analysis by Mid Clinical Stage Development, H1 2012 25 Comparative Analysis by Early Clinical Stage Development, H1 2012 26 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 27 Products under Development by Companies, H1 2012 28 Products under Investigation by Universities/Institutes, H1 2012 29 Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 30 Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 31 Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 32 Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 33 Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 34 Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 35 Alkermes, Inc., H1 2012 36 Nippon Shinyaku Co., Ltd., H1 2012 37 Mundipharma International Limited, H1 2012 38 Snowdon Inc., H1 2012 39 KYORIN Pharmaceutical Co., Ltd., H1 2012 40 Embera NeuroTherapeutics, Inc., H1 2012 41 Celtic Pharmaceutical Holdings L.P., H1 2012 42 Assessment by Monotherapy Products, H1 2012 43 Assessment by Combination Products, H1 2012 44 Assessment by Stage and Route of Administration, H1 2012 46 Assessment by Molecule Type, H1 2012 48 Substance (Drug) Abuse Therapeutics – Drug Profile Updates 158 Substance (Drug) Abuse Therapeutics – Discontinued Products 162 Substance (Drug) Abuse Therapeutics – Dormant Products 163 Substance (Drug) Abuse Therapeutics – Dormant Products (Contd..1) 164 Substance (Drug) Abuse Therapeutics – Dormant Products (Contd..2) 165 Substance (Drug) Abuse Therapeutics – Dormant Products (Contd..3) 166 Substance (Drug) Abuse Therapeutics – Dormant Products (Contd..4) 167 Substance (Drug) Abuse Therapeutics – Dormant Products (Contd..5) 168 List of Figures Number of Products under Development for Substance (Drug) Abuse, H1 2012 16 Products under Development for Substance (Drug) Abuse – Comparative Analysis, H1 2012 17 Products under Development by Companies, H1 2012 18 Products under Investigation by Universities/Institutes, H1 2012 20 Late Stage Products, H1 2012 24 Mid Clinical Stage Products, H1 2012 25 Early Clinical Stage Products, H1 2012 26 Discovery and Pre-Clinical Stage Products, H1 2012 27 Assessment by Monotherapy Products, H1 2012 43 Assessment by Combination Products, H1 2012 44 Assessment by Route of Administration, H1 2012 45 Assessment by Stage and Route of Administration, H1 2012 46 Assessment by Molecule Type, H1 2012 47 Assessment by Stage and Molecule Type, H1 2012 48 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
